Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients with femoropopliteal artery disease, which caused the interruption of a few ongoing studies, reality indicates that the efficacy of these devices has been proven and that they are still used. The increased mortality observed in the meta-analysis that<a href="https://solaci.org/en/2019/04/09/drug-eluting-stents-vs-balloons-while-paclitaxel-is-in-the-eye-of-the-storm/" title="Read more" >...</a>
The beneficial effect of low dose drug coated balloons with paclitaxel is sustained in time according to this randomized study. In a nutshell, this study has shown a significant statistical difference in favor of paclitaxel coated balloons vs. conventional PCI at 2 years. The safety and efficacy of new generation low dose drug coated balloons<a href="https://solaci.org/en/2019/02/04/long-term-effect-of-low-dose-paclitaxel-coated-balloon/" title="Read more" >...</a>
In patients with symptomatic peripheral vascular disease, the paclitaxel coated balloon showed superior efficacy at 3 years compared to the conventional balloon, in addition to very good results at one year when tested in the real world outside strict trial inclusion/exclusion criteria. Both the IN.PACT SFA trial and the IN.PACT SFA global registry showed<a href="https://solaci.org/en/2016/10/11/paclitaxel-drug-coated-balloon-in-femoral-effective-at-long-term-2/" title="Read more" >...</a>
Fundamentos: O objetivo desse estudo apresentado na sessão First Report Investigations foi comparar a eficácia anti reestenose da pré-dilatação com scoring balloon versus balão convencional antes do tratamento com balão com cobertura de Paclitaxel em pacientes com reestenose após implante de stent farmacológico. Métodos e resultados: Foi um estudo multicêntrico, prospectivo e randomizado que incluiu pacientes com<a href="https://solaci.org/en/2015/10/13/isar-desire-4-balon-liberador-de-paclitaxel-en-reestenosis-intrastent-de-un-des-2/" title="Read more" >...</a>
Fundamentos: Os stents farmacológicos (DES) diminuem as taxas de reestenose, no entanto, ainda existem preocupações sobre a segurança e eficácia da utilização de balões eluidores de drogas após o implante de stents convencionais, especialmente no infarto do miocárdio com elevação do segmento ST (STEMI). Objetivos: O objetivo deste estudo foi avaliar a segurança e a<a href="https://solaci.org/en/2015/06/24/congress-item-8925/" title="Read more" >...</a>
Fundamentals. Background: Although we’ve had more than a decade of experience with implanting drug-eluting stents, (DES), the best treatment for restenosis on these devices remains unknown. The drug-eluting balloons are a promising alternative which avoid the possibility of a new layer of metal on the restenotic injury. This study compared the performance of these balls<a href="https://solaci.org/en/2015/06/24/congress-item-7091/" title="Read more" >...</a>
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/n-4418/" title="Read more" >...</a>
Original title: Paclitaxel – coated balloon catheter compared with drug- eluting stent for drug-eluting stent restenosis in routine clinical practice. Reference: SeijiHabara et al.EuroIntervention 2015; 10-online publish-ahead-of-printFebruary 2015. The paclitaxel coated balloon catheter (PCB) is not inferior to DES for the treatment of instent restenosis (IRS). The aim of this study is to compare the efficacy of the<a href="https://solaci.org/en/2015/03/12/n-5055/" title="Read more" >...</a>
Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/n-3648/" title="Read more" >...</a>